DOES LONG-TERM TREATMENT WITH ENALAPRIL AFFECT BLOOD LEVEL OF INSULINAND OTHER COMPONENTS OF METABOLIC SYNDROME IN HYPERTENSION

Effects of an angiotensin converting enzyme inhibitor enalapril were s tudied in 15 nondiabetic patients (age 47,9 +/- 3,2 years) with stage I-II essential hypertension, pronounced hyperinsulinemia and hyper-C-p eptidemia (fasting and after glucose load), dyslipidemia and body mass index over 30. None of the patients had ischemic heart disease or any other disease associated with disorder of lipid or carbohydrate metab olism. Seven patients received open enalapril maleate for 12 months (a verage dose 16,7 +/- 4 mg/day), 8 patients served as controls. At rest udy after 12 months significant positive changes of fasting and postpr andial levels of insulin and C-peptide, and of triglycerides occurred in 6 of 7 patients in intervention group while no such changes were re gistered in control group. As positive dynamics of parameters studied was not accompanied by changes of body weight it could be concluded th at at least in obese middle-aged insulin resistant hypertensives impro vement of metabolic parameters was caused by long term enalapril thera py.